Tumor necrosis factor-alpha - potential target for neuroprotector dimebon

Alessenko A.V.1 , Bachurin S.O.2, Gurianova S.V.3, Karatasso Y.O.1, Shevtsova E.F.2, Shingarova L.N.3

1. Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences, Moscow, Russia
2. Institute of Physiologically Active Substances of the Russian Academy of Sciences, Chernogolovka, Russia
3. Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
Section: Experimental Study
DOI: 10.18097/PBMC20166204418      PubMed Id: 27562995
Year: 2016  Volume: 62  Issue: 4  Pages: 418-425
Dimebon (Dimebolin) is an antihistamine drug which has been used in Russia since 1983. Recently Dimebolin has attracted renewed interest after being shown to have positive effects on persons suffering from Alzheimer's disease. Animal studies have shown that dimebon acts through multiple mechanisms, both blocking the action of neurotoxic beta-amyloid peptides and inhibiting L-type calcium channels, modulating the action of AMPA and NMDA glutamate receptors. Our experiments with cell culture L929 and mice have shown that dimebon may exert its neuroprotective effect by blocking cytotoxic signals induced by proinflammatory cytokines such as TNF-a which are believed to play a central role in Alzheimer's disease. Dimebon (10 mg/ml) protected mouse fibroblasts L929 against the toxic action of TNF-a. Our study included 65 male mice. TNF-a (10 mg per mouse), dimebon (0,2 mg/kg) and their combination were injected intraperitonealy. Changes in the level of molecular species of sphingomyelin and galactosyl ceramide in hippocampus, cerebellum and cerebral cortex within 30 min, 2 h, 4 h, and 24 h after injection were detected by chromato-mass-spectrometry. Maximal changes in sphingomyelin and galactosyl ceramides contents of different molecular species after single TNF-a administration were found in the hippocampus, and were less expressed in the cerebral cortex and cerebellum after 24 h. Dimebon itself did not induce changes in the sphingolipid spectrum in brain sections, but protected them against disorders induced by TNF-a in the brain. Modern strategies in the search of new therapeutic approaches are based on the multitarget properties of new drugs. According to our results TNF-a may serve as a new target for dimebon.
Download PDF:  
Keywords: dimebon, TNF-alpha, lipids, mice brain, mice fibroblasts L929

Alessenko, A. V., Bachurin, S. O., Gurianova, S. V., Karatasso, Y. O., Shevtsova, E. F., Shingarova, L. N. (2016). Tumor necrosis factor-alpha - potential target for neuroprotector dimebon. Biomeditsinskaya Khimiya, 62(4), 418-425.
This paper is also available as the English translation: 10.1134/S199075081502002X
 2024 (vol 70)
 2023 (vol 69)
 2022 (vol 68)
 2021 (vol 67)
 2020 (vol 66)
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)